New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
16:46 EDTREGNRegeneron recommends rejection of mini-tender offer by TRC Capital
Regeneron Pharmaceuticals (REGN) has been notified of an unsolicited "mini-tender" offer by TRC Capital to purchase up to 1M shares, or approximately 1.06%, of the outstanding Regeneron common stock at a price of $161.25 per share. TRC's offer price represents approximately a 4.46% discount to the closing price of Regeneron common stock on December 27, 2012, the last closing price prior to commencement of the offer, and a 10.77% discount to the closing price of Regeneron common stock on January 3, 2013. In addition, TRC's offer is subject to numerous conditions, including the availability of financing satisfactory to TRC. Regeneron does not endorse TRC's offer and recommends that shareholders do not tender their shares in response to the offer because it is a so-called "mini-tender" offer at a price below the current market price for Regeneron shares and is subject to numerous conditions. Regeneron urges shareholders considering TRC's offer to obtain current market quotations for their shares, review the conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC's offer. Regeneron is not associated in any way with TRC, its mini-tender offer or the offer documentation. According to TRC's current offer documents, Regeneron shareholders who have tendered their shares may withdraw their shares at any time prior to 12:01 a.m., New York City time, on Tuesday, January 29, 2013, the expiration date set forth in the offer documents (unless extended), by following the procedures described in the offer documents.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information
August 31, 2014
14:22 EDTREGNSanofi, Regeneron announce results from four Phase 3 ODYSSEY trials
Subscribe for More Information
13:59 EDTREGNRW Baird to hold a conference
Subscribe for More Information
13:41 EDTREGNCitigroup to hold a conference
Subscribe for More Information
12:50 EDTREGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
12:23 EDTREGNNovartis drug data to be presented this weekend
Subscribe for More Information
August 25, 2014
11:48 EDTREGNSanofi and Regeneron co-host a conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use